Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
6.53
-0.35 (-5.09%)
At close: Mar 28, 2025, 4:00 PM
6.69
+0.16 (2.45%)
After-hours: Mar 28, 2025, 6:36 PM EDT
Atara Biotherapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Atara Biotherapeutics stock have an average target of 25.7, with a low estimate of 11 and a high estimate of 57.5. The average target predicts an increase of 293.57% from the current stock price of 6.53.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Atara Biotherapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 6 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +160.34% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 22, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $21 → $17 | Strong Buy | Maintains | $21 → $17 | +160.34% | Jan 17, 2025 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +282.85% | Dec 20, 2024 |
Financial Forecast
Revenue This Year
82.67M
from 128.94M
Decreased by -35.89%
Revenue Next Year
71.20M
from 82.67M
Decreased by -13.87%
EPS This Year
-9.34
from -11.41
EPS Next Year
-1.68
from -9.34
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 162.8M | 134.4M | 350.0M | ||
| Avg | 82.7M | 71.2M | 181.3M | ||
| Low | 32.3M | 2.9M | 83.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.2% | 62.6% | 391.6% | ||
| Avg | -35.9% | -13.9% | 154.7% | ||
| Low | -74.9% | -96.4% | 17.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -8.36 | -1.24 | 0.54 | |
| Avg | -9.34 | -1.68 | -2.93 | |
| Low | -10.25 | -2.08 | -6.13 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.